Immunotherapies have led to substantial changes in cancer treatment and have been a
persistently popular topic in cancer research because they tremendously improve the …

More than 1.6 million new cases of cancer will be diagnosed in the US in 2016, resulting in
more than 500,000 deaths. Although chemotherapy has been the mainstay of treatment in …

Defects in the DNA mismatch repair (MMR) proteins, result in a phenotype called
microsatellite instability (MSI), occurring in up to 15% of sporadic colorectal cancers …

Purpose The clinicopathologic significance of mismatch repair (MMR) defects in
endometrioid endometrial cancer (EEC) has not been definitively established. We undertook …

In recent years, it has become evident that tumor cells have immune escape mechanisms,
and immune checkpoint inhibitor therapy (anti-PD-1/PD-L1 antibody) has shown benefit in …

The pathogenesis of DNA mismatch repair (MMR)-deficient endometrial carcinoma (EC) is
driven by inactivating methylation or less frequently mutation of an MMR gene (MLH1 …

Simple Summary Identification of mismatch repair-deficient tumors (MMRd), which occur in
up to 30% of all endometrial cancers (EC), has become unavoidable for therapeutic …

Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among women.
Two-thirds of patients present at advanced stage at diagnosis, and the estimated 5 year …

Lynch syndrome, an autosomal dominant inherited disorder, is caused by inactivating
mutations involving DNA mismatch repair (MMR) genes. This leads to profound genetic …

Background The objective of this study was to assess the correlation between mismatch
repair (MMR) status, disease recurrence patterns, and recurrence‐free survival (RFS) in …